cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2012-5-74-78cardiovascular-1923Research ArticleОБЗОРЫREVIEWSРоль маркеров воспаления при фибрилляции предсердий (обзор)The role of inflammatory markers in atrial fibrillation: a reviewГригорянС. В.GrigoryanS. V.

(контактное лицо) – научный руководитель отделения аритмии; 

профессор кафедры кардиологии факультета постдипломного обучения

Тел.: 37591415123

s.grigoryan@interdiagnostika.comАдамянК. Г.AdamyanK. G.

научный руководитель отделения острого инфаркта; 

зав. кафедрой кардиологии факультета постдипломного обучения

Тел.: 37591415123

s.grigoryan@interdiagnostika.comАзарапетянЛ. Г.AzarapetyanL. G.

ассистент кафедры кардиологии факультета постдипломного обучения

Тел.: 37591415123

s.grigoryan@interdiagnostika.comНИИ кардиологии; ЕГМУ им. М.Гераци, ЕреванResearch Institute of Cardiology; M. Geratsi Yerevan State Medical University, YerevanЕГМУ им. М.Гераци, ЕреванM. Geratsi Yerevan State Medical University, Yerevan2012201020121157478Copyright © Григорян С.В., Адамян К.Г., Азарапетян Л.Г., 20122012Григорян С.В., Адамян К.Г., Азарапетян Л.Г.Grigoryan S.V., Adamyan K.G., Azarapetyan L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1923

В обзоре обсуждается роль латентного воспаления в патогенезе фибрилляции предсердий (ФП). Представлены современные работы и суждения по поводу влияния уровней концентрации маркеров воспаления на возникновение и возможные рецидивы ФП. Обсуждается подготовка базиса для использования плейотропных эффектов препаратов при лечении и профилактике ФП.

This review is focused on the role of latent inflammation in atrial fibrillation (AF) pathogenesis. The modern views and available evidence on the association between the levels of inflammatory markers and AF development and recurrence are presented. The justification for the use of pleiotropic effects of pharmacological therapy in AF prevention and treatment is discussed.

фибрилляция предсердиймаркеры воспалениявоспалениерецидив фибрилляции предсердийatrial fibrillationinflammatory markersinflammationrecurrent atrial fibrillationReferencesAdamyan KG, Grigoryan SV,Yazarapetyan LG. The role of inflammation in pathogenesis of atrial fibrillation. Vestnik Arrythmology 2008; 54: 34-1. Russian (Адамян К.Г., Григорян С.В., Азарапетян Л.Г. Роль латентного воспаления в патогенезе фибрилляции предсердий. Вестник аритмологии 2008; 54: 34-41).Adamyan KG, Grigoryan SV,Yazarapetyan LG. The role of inflammation in pathogenesis of atrial fibrillation. Vestnik Arrythmology 2008; 54: 34-1. Russian (Адамян К.Г., Григорян С.В., Азарапетян Л.Г. Роль латентного воспаления в патогенезе фибрилляции предсердий. Вестник аритмологии 2008; 54: 34-41).Hazarapetyan LG, Budagyan LG, Grigoryan SV, et al. The prognostic value of some inflammation markers in different types of atrial fibrillation. In book “VII Congress of Armenian Cardiologists” 2009; 104-7. Russian (Азарапетян Л.Г., Будагян Л.Г., Григорян С.В. и др. Прогностическая значимость некоторых маркеров воспаления при различных клинических формах мерцательнорй аритмии. Научные труды VII Конгресса кардиологов Армении 2009; 104-7).Hazarapetyan LG, Budagyan LG, Grigoryan SV, et al. The prognostic value of some inflammation markers in different types of atrial fibrillation. In book “VII Congress of Armenian Cardiologists” 2009; 104-7. Russian (Азарапетян Л.Г., Будагян Л.Г., Григорян С.В. и др. Прогностическая значимость некоторых маркеров воспаления при различных клинических формах мерцательнорй аритмии. Научные труды VII Конгресса кардиологов Армении 2009; 104-7).Volkov VI, Salamech ChN, Serik SA. Role of pro- and anti-inflammation cytokines in heart failure In book: Scientific works of Charkov Med. Institute 2007; 2: 23-8. Russian (Волков В.И., Саламех Х.Н., Серик С.А. Про- и противовоспалительные цитокины при сердечной недостаточности. В сб: Научные труды. Харьк. гос. мед. институт 2007; 2: 23-8).Volkov VI, Salamech ChN, Serik SA. Role of pro- and anti-inflammation cytokines in heart failure In book: Scientific works of Charkov Med. Institute 2007; 2: 23-8. Russian (Волков В.И., Саламех Х.Н., Серик С.А. Про- и противовоспалительные цитокины при сердечной недостаточности. В сб: Научные труды. Харьк. гос. мед. институт 2007; 2: 23-8).Grigoryan SV, Hazarapetyan LG. The role of inflammation markers in outcome of atrial fibrillation. In book: The scientific works of the Congress “The Men and Health” 2007, Yerevan 46-50. Russian ( Григорян С.В., Азарапетян Л.Г. Роль маркеров воспаления в патогенезе мерцательной аритмии. В сб: Научные труды Конгресса «Человек и здоровье» 2007, Ереван, 46-50).Grigoryan SV, Hazarapetyan LG. The role of inflammation markers in outcome of atrial fibrillation. In book: The scientific works of the Congress “The Men and Health” 2007, Yerevan 46-50. Russian ( Григорян С.В., Азарапетян Л.Г. Роль маркеров воспаления в патогенезе мерцательной аритмии. В сб: Научные труды Конгресса «Человек и здоровье» 2007, Ереван, 46-50).Gurevich MA. The practical aspects of atrial fibrillation etiology and treatment. Cardiologia 2001; 7: 14-8. Russian (Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии. Кардиология 2001; 7: 14-8).Gurevich MA. The practical aspects of atrial fibrillation etiology and treatment. Cardiologia 2001; 7: 14-8. Russian (Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии. Кардиология 2001; 7: 14-8).Kuschakovskij M.S. Heart arrhythmia. The handbook for doctors. “Foliant” 2004, 672. Russian (Кушаковский М.С. Аритмии сердца. Руководство для врачей. СПб.: ИКФ «Фолиант» 2004; 672 с).Kuschakovskij M.S. Heart arrhythmia. The handbook for doctors. “Foliant” 2004, 672. Russian (Кушаковский М.С. Аритмии сердца. Руководство для врачей. СПб.: ИКФ «Фолиант» 2004; 672 с).Nasonov EL, Panjukova EL, Aleksandrova EN. CRP – inflammation marker of atherosclerosis (new data). Kardiologia 2002; 7: 53-62. Russian (Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок – маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-62).Nasonov EL, Panjukova EL, Aleksandrova EN. CRP – inflammation marker of atherosclerosis (new data). Kardiologia 2002; 7: 53-62. Russian (Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок – маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-62).Olbinskaja LI, Ignatenko S.B. The role of cytokines in develop of heart kachexia in patients with heart failure. Heart Failure 2001; 2,3: 33-9. Russian (Ольбинская Л.И., Игнатенко С.Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью. Ж Сердечная недостаточность 2001; 2, 3: 33-9).Olbinskaja LI, Ignatenko S.B. The role of cytokines in develop of heart kachexia in patients with heart failure. Heart Failure 2001; 2,3: 33-9. Russian (Ольбинская Л.И., Игнатенко С.Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью. Ж Сердечная недостаточность 2001; 2, 3: 33-9).Tarasova O.A. Inflammation markers in atrial fibrillation. Vrach 2007; 1(16): 49-53. Russian (Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий. Врач 2007; 1(16): 49-53).Tarasova O.A. Inflammation markers in atrial fibrillation. Vrach 2007; 1(16): 49-53. Russian (Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий. Врач 2007; 1(16): 49-53).Abdelhadi RH, Chung MK, Wagoner D.R., New hope for the prevention of recurrent atrial fibrillation (Bruins P, Velthius H, Yazdanbakkhsh A, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves CRP and it si associated with postoperative arrhythmia. Circulation 1997; 96: 3542-8.Abdelhadi RH, Chung MK, Wagoner D.R., New hope for the prevention of recurrent atrial fibrillation (Bruins P, Velthius H, Yazdanbakkhsh A, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves CRP and it si associated with postoperative arrhythmia. Circulation 1997; 96: 3542-8.Ashikaga H, Marine JE. Prevention of atrial fibrillation: another good reason to recommend statins to women? Heart 2009; 95: 693-4.Ashikaga H, Marine JE. Prevention of atrial fibrillation: another good reason to recommend statins to women? Heart 2009; 95: 693-4.Aviles RJ, Martin DO, Apperson-Hansen C, et al. Infiammation as a rick factor for atrial fibrillation. Circulation 2003; 108 (24): 3006-10.Aviles RJ, Martin DO, Apperson-Hansen C, et al. Infiammation as a rick factor for atrial fibrillation. Circulation 2003; 108 (24): 3006-10.Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrence lone atrial fibrillation by the angiotensin II converting Enzyme inhibitor ramipril in normotensive patients. JACC 2009; 53: 24-9.Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrence lone atrial fibrillation by the angiotensin II converting Enzyme inhibitor ramipril in normotensive patients. JACC 2009; 53: 24-9.Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004; 110: 560-7.Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004; 110: 560-7.Boss ChJ, Lip GYH. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathology to clinical trials. J Hum Hypertens 2005; 19: 855-9.Boss ChJ, Lip GYH. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathology to clinical trials. J Hum Hypertens 2005; 19: 855-9.Boss ChJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorders? Eur Heart J 2006; 27: 136-49.Boss ChJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorders? Eur Heart J 2006; 27: 136-49.Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. JACC 1998; 32(7): 2057-64.Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. JACC 1998; 32(7): 2057-64.Califf R and Fox AA. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159(3): 340-7.Califf R and Fox AA. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159(3): 340-7.Cheruku KK, Ghani A, Ahmad F, et al. Efficacy of nonsteroidal antiinflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery. Prev Cardiol 2004; 7: 13-8.Cheruku KK, Ghani A, Ahmad F, et al. Efficacy of nonsteroidal antiinflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery. Prev Cardiol 2004; 7: 13-8.Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006; 37: 482-6.Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006; 37: 482-6.Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 22, 321(7255): 199-204.Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 22, 321(7255): 199-204.Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 12-4.Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 12-4.Engelmann MDM, Svedsen JH. Inflammation in the genesis of atrial fibrillation. Eur Heart J 2005; 20(26): 2083-92.Engelmann MDM, Svedsen JH. Inflammation in the genesis of atrial fibrillation. Eur Heart J 2005; 20(26): 2083-92.Engelmann MD, Svedsen JH. The emerging role of inflammation in atrial fibrillation and the potential of anti-inflammatory intervention: reply. Eur Heart J 2005; 26 (20): 2208-9.Engelmann MD, Svedsen JH. The emerging role of inflammation in atrial fibrillation and the potential of anti-inflammatory intervention: reply. Eur Heart J 2005; 26 (20): 2208-9.Engelmann MD, Ogard CG, Niemann L, et al. Increased levels of multiple markers of inflammation in patients with persistent atrial fibrillation. Scan Cardiovasc J 2005; 39: 36.Engelmann MD, Ogard CG, Niemann L, et al. Increased levels of multiple markers of inflammation in patients with persistent atrial fibrillation. Scan Cardiovasc J 2005; 39: 36.Grigoryan SV, Hazarapetyan LG, Stepanyan AA. Inhibitor of angiottnsini II type I receptors Eprosartan and Amiodarone as a combined treatment of advanced heart failure and atrial fibrillation. International Congress on Heart Failure 2007; 233.Grigoryan SV, Hazarapetyan LG, Stepanyan AA. Inhibitor of angiottnsini II type I receptors Eprosartan and Amiodarone as a combined treatment of advanced heart failure and atrial fibrillation. International Congress on Heart Failure 2007; 233.Grigoryan SV, Adamyan KG., Hazarapetyan LG. Tumor necrosis factor -aGrigoryan SV, Adamyan KG, Hazarapetyan LG. Association between inflammation markers and recurrence of atrial fibrillation after successful cardioversion. ESC Congress Barselona 2009;78.Grigoryan SV, Adamyan KG., Hazarapetyan LG. Tumor necrosis factor -aGrigoryan SV, Adamyan KG, Hazarapetyan LG. Association between inflammation markers and recurrence of atrial fibrillation after successful cardioversion. ESC Congress Barselona 2009;78.Grigoryan SV, Adamyan KG, HazarapetyanL G, et al . Atrial fibrillation and anti-inflammatory medication with Nimesulde, ESC Congress StockholmSweden 27 August - 1 September 2010, 31.Grigoryan SV, Adamyan KG, HazarapetyanL G, et al . Atrial fibrillation and anti-inflammatory medication with Nimesulde, ESC Congress StockholmSweden 27 August - 1 September 2010, 31.Ford ES, Giles WH. Serum C-reactive protein and self- reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arteriocler Thromb Vasс Biol 2000; 20: 1052-6.Ford ES, Giles WH. Serum C-reactive protein and self- reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arteriocler Thromb Vasс Biol 2000; 20: 1052-6.Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target. Rev Esp Cardiol 2006; 59: 94-8.Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target. Rev Esp Cardiol 2006; 59: 94-8.Issac TT, Dokanish H, Lakkis NM. C-reactive protein and atrial fibrillation. Am J Cardiol 2007; 11: 443-5.Issac TT, Dokanish H, Lakkis NM. C-reactive protein and atrial fibrillation. Am J Cardiol 2007; 11: 443-5.Lee KWJ, Hill JS, Walley KR, et al. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 2006; 174: 461-6.Lee KWJ, Hill JS, Walley KR, et al. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 2006; 174: 461-6.Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardiovertion. Am J Cardiol 2007; 99: 1421-4.Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardiovertion. Am J Cardiol 2007; 99: 1421-4.Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Circulation 2000; 102: 1755-60.Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Circulation 2000; 102: 1755-60.Ockene LS, Mathews CD, Rifai N, et al. Validity and classification accuracy of serial nigh-sensitive C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444-50.Ockene LS, Mathews CD, Rifai N, et al. Validity and classification accuracy of serial nigh-sensitive C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444-50.Pepys M.B, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.Pepys M.B, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.Ridker PM. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-21.Ridker PM. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-21.Schonbek U, Libby P. Inflammation, Immunity, and HMG-CjA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation 2004; 109: 18-26.Schonbek U, Libby P. Inflammation, Immunity, and HMG-CjA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation 2004; 109: 18-26.Sideris AN, Letsas K. Inflammation and Atrial Fibrillation. Hospital Chronicles 2006; Suppl. 128-34.Sideris AN, Letsas K. Inflammation and Atrial Fibrillation. Hospital Chronicles 2006; Suppl. 128-34.Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structual remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005; 20(2): 45-9.Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structual remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 2005; 20(2): 45-9.Wazni O, Martin DO, Marrouche NF, et al. Creacrive protein concentration and reccurence of atrial fibrillation after electrical cardioversion. Heart 2005; 91: 1303-5.Wazni O, Martin DO, Marrouche NF, et al. Creacrive protein concentration and reccurence of atrial fibrillation after electrical cardioversion. Heart 2005; 91: 1303-5.

The authors declare that there are no conflicts of interest present.